STOCK TITAN
  1. Home
  2. News
  3. SXTP

60 Degrees Pharmaceuticals, Inc. - SXTP STOCK NEWS

Welcome to our dedicated page for 60 Degrees Pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals stock.

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) is a specialty pharmaceutical company focused on the development and commercialization of new therapies for the prevention and treatment of infectious diseases. Founded in 2010 and headquartered in Washington D.C., the company leverages biological science and applied research to combat various viral, fungal, and tick-borne diseases.

60 Degrees Pharmaceuticals' flagship product, ARAKODA® (tafenoquine), received FDA approval in 2018 for malaria prophylaxis in patients aged 18 years and older. ARAKODA® is also approved in Australia under the name KODATEF® and was launched commercially in both countries in 2019. It is available through pharmaceutical wholesaler networks and retail pharmacies as a prescription-only medication. The drug's long terminal half-life, approximately 16 days, offers potential advantages in reducing the frequency of doses required for malaria prevention.

Currently, the company is expanding its research scope to include other indications for tafenoquine, notably the treatment of acute babesiosis, a tick-borne disease. The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to tafenoquine for this purpose. This designation provides 60 Degrees Pharmaceuticals with various incentives, including market exclusivity, tax credits, and fee exemptions.

In addition to its work on babesiosis, the company is developing treatment options for COVID-19 and other infectious diseases. This includes a pilot study to evaluate the efficacy of tafenoquine in treating canine babesiosis, conducted in collaboration with North Carolina State University.

60 Degrees Pharmaceuticals continues to collaborate with prominent research organizations in the U.S., Australia, and Singapore. The company's research and development efforts have received in-kind support from the U.S. Department of Defense and private institutional investors like Knight Therapeutics Inc. The firm remains committed to advancing its pipeline products and supporting clinical trials that could significantly impact public health.

For more information about their products, ongoing trials, and latest news updates, visit www.60degreespharma.com.

News

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. appoints Kristen Landon as Chief Commercial Officer to lead U.S. relaunch of ARAKODA® for malaria prevention. The company plans to expand clinical research in tick-borne diseases beyond acute babesiosis. Landon brings over 26 years of commercial leadership experience in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
management
-
News

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Rhea-AI Summary
WallachBeth Capital LLC announced that 60 Degrees Pharmaceuticals, Inc. completed a Public Offering of 5,260,901 units and 999,076 pre‑funded units at specific prices. The underwriters were granted an option to purchase additional shares, Warrants, and/or Pre-Funded Warrants. WallachBeth Capital LLC partially exercised its over-allotment option with respect to 818,177 Warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.75%
Tags
offering
-
News

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced the closing of its public offering of 5,260,901 units and 999,076 pre-funded units. The company intends to use the net proceeds for working capital, relaunch of ARAKODA®, and research and development activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.75%
Tags
offering
News

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Rhea-AI Summary
WallachBeth Capital LLC announced the pricing of 60 Degrees Pharmaceuticals, Inc.'s public offering of units and pre-funded units. The Units were priced at $0.385 per unit, and the Pre-Funded Units were priced at $0.375 per unit. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.58%
Tags
offering
-
News

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. announced the pricing of its public offering of 5,260,901 units and 999,076 pre-funded units at $0.385 and $0.375 per unit respectively. Each unit consists of one share of common stock and one warrant exercisable for one share of common stock. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.58%
Tags
offering
-
News

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) plans to conduct a pivotal clinical study for the treatment of hospitalized babesiosis patients with tafenoquine following a Type C meeting with FDA. The FDA indicated that the proposed study could be sufficient for regulatory approval, provided the Company uses a clinical endpoint rather than a surrogate marker. Patient enrollment is expected to begin in the summer of 2024. The company aims to address the unmet medical need for a new therapeutic for hospitalized babesiosis patients, with an estimated 47,000 cases per year in the U.S. Tafenoquine is currently approved for malaria prophylaxis and has been assessed in multiple trials for safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.97%
Tags
none
News

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) has announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market after receiving a written notice from the Nasdaq Listing Qualifications Staff. The Company was previously notified of non-compliance due to its common stock failing to maintain a minimum bid price of $1.00 for 30 consecutive business days. However, it has now achieved compliance by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
News

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced the Investigational Review Board (IRB) approval for a Phase IIA clinical study to investigate tafenoquine for the treatment of hospitalized babesiosis patients. The previously announced Type C meeting with the FDA has been rescheduled to January 17, 2024, due to a federal holiday.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.09%
Tags
acquisition clinical trial
-
News

Thinking about buying stock in Sportsmap Tech Acquisition, Dune Acquisition, Macy's, Cybin, or 60 Degrees Pharmaceuticals?

Rhea-AI Summary
InvestorsObserver Critical PriceWatch Alerts: MSAI, DUNE, M, CYBN, and SXTP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
acquisition
News

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced a Type C meeting with the FDA to discuss a proposed Phase II study of tafenoquine for the treatment of babesiosis, a life-threatening parasitic disease transmitted by ticks. The meeting is scheduled for January 15, 2024. Tafenoquine is currently approved for malaria prophylaxis but not for babesiosis treatment. The Company plans to conduct a clinical study to evaluate its use for this purpose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.93%
Tags
acquisition

FAQ

What is the current stock price of 60 Degrees Pharmaceuticals (SXTP)?

The current stock price of 60 Degrees Pharmaceuticals (SXTP) is $0.891 as of November 4, 2024.

What is the market cap of 60 Degrees Pharmaceuticals (SXTP)?

The market cap of 60 Degrees Pharmaceuticals (SXTP) is approximately 1.7M.

What does 60 Degrees Pharmaceuticals specialize in?

60 Degrees Pharmaceuticals focuses on developing and commercializing new therapies for the prevention and treatment of infectious diseases.

What is ARAKODA®?

ARAKODA® is an FDA-approved antimalarial drug containing tafenoquine, used for malaria prophylaxis in patients aged 18 years and older.

What recent achievements has 60 Degrees Pharmaceuticals made?

The company received FDA orphan drug designation for tafenoquine for treating acute babesiosis and is conducting multiple studies on its efficacy for other conditions.

What are the current projects of 60 Degrees Pharmaceuticals?

Current projects include developing treatments for COVID-19, babesiosis, and other viral and tick-borne diseases.

Who are 60 Degrees Pharmaceuticals' key collaborators?

The company collaborates with the U.S. Department of Defense, Knight Therapeutics Inc., and various research organizations in the USA, Australia, and Singapore.

Where is 60 Degrees Pharmaceuticals headquartered?

The company is headquartered in Washington D.C., with a majority-owned subsidiary in Australia.

How can I get more information about ARAKODA®?

For detailed prescribing information and safety guidelines, visit the official website at www.60degreespharma.com.

Is tafenoquine approved for treating babesiosis?

Tafenoquine is not yet FDA-approved for treating babesiosis, but it has received orphan drug designation, and clinical trials are ongoing.

How is 60 Degrees Pharmaceuticals funded?

The company receives support from the U.S. Department of Defense, private institutional investors like Knight Therapeutics Inc., and public offerings.

How can I stay updated on the latest news from 60 Degrees Pharmaceuticals?

You can visit their website at www.60degreespharma.com for the latest updates and news releases.

Stock SXTP logo
60 Degrees Pharmaceuticals, Inc.

Nasdaq:SXTP

SXTP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SXTP Stock Data

1.66M
1.86M
10.58%
1.6%
0.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WASHINGTON